ArticleInfectious diseases & immunity2025
Immune response dynamics to SARS-CoV-2 in the Albanian population: A study on T-cell and antibody interactions during the transition from pandemic to endemic phase.
Article in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has resulted in a dynamic evolution of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initially characterized by primary responses and later by secondary responses due to mass vaccination and viral variants. Understanding the interplay between humoral (antibody) and cellular (T-cell) immunity is crucial for effective public health strategies. This study aims to evaluate the correlation between T-cell responses and antibody levels in a sample of the adult Albanian population during the transition of COVID-19 from a pandemic to an endemic phase. The rationale for this investigation is to generate data that can inform the ongoing management of COVID-19, particularly in the context of vaccination and immunity monitoring, to ensure that public health strategies remain effective as the virus becomes more permanent in the population. Methods: This cross-sectional observational study involved individuals over 18 years of age who were randomly selected at intervals of every 20 records from the family doctor registries of five urban health centers in Tirana and Berat, Albania, between January 23 and April 3, 2023. Participants provided demographic and health data, including vaccination and infection history. Blood samples were analyzed for cellular immunity using an Interferon-gamma (IFN-γ) release assay and for humoral immunity using the enzyme-linked immunosorbent assay to measure anti-spike (S1) and anti-nucleoprotein (N) IgG antibodies. Statistical analyses were conducted to examine the relationships between levels of IFN-γ, anti-S1, and anti-N IgG antibodies and factors such as vaccination status, prior COVID-19 infections, and reinfection rates. These analyses employed bivariate and multivariate approaches, including Fisher's exact test, the Mann-Whitney Results: The study involved 164 individuals (54.7% [90/164] female, median age 43 years). Of these individuals, 62.8% (103/164) were vaccinated, primarily with the Pfizer-BioNTech vaccine. IFN-γ positivity was detected in 95.1% (156/164), and anti-S1 IgG positivity in 93.3% (153/164). Significant correlations were observed between IFN-γ and anti-S1 IgG levels ( Conclusion: Vaccination, especially when combined with previous infection, significantly boosts both cellular and humoral immunity against SARS-CoV-2. The close correlation between IFN-γ and anti-S1 IgG levels indicates that vaccinated individuals mount a robust immune response. The lower reinfection rates among vaccinated individuals highlight the importance of vaccination for sustained protection. Assessing anti-S1 IgG antibodies and IFN-γ levels could be particularly beneficial for immunocompromised individuals when making decisions about revaccination. This study highlights the critical role of comprehensive immune monitoring in the management of COVID-19 and offers insights for future vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.